Moderna (MRNA) shares surged 16% to a 52-week high of 50 Wednesday after five-year cancer vaccine trial data showed significant melanoma risk reduction.
The results strengthen Moderna’s oncology pipeline beyond COVID vaccines, potentially expanding its addressable market and revenue diversification prospects.
Key Takeaways
- Five-year trial data shows 49% melanoma recurrence risk reduction
- Stock reaches 50 high, up 69% year-to-date
- Partnership with Merck advances personalized cancer vaccine approach
Market reaction & context
Moderna’s stock jumped 16% in Wednesday trading, hitting 50 for the first time in over a year 3. The biotech company has now gained 69% this year, recovering from a 29% decline in 2024 as investors shifted focus from COVID products to its broader pipeline 1.
The rally outpaced the broader biotechnology sector, with the SPDR S&P Biotech ETF (XBI) gaining just 2% on Wednesday. Moderna’s market capitalization now exceeds 18 billion.
Trial results drive optimism
Moderna and Merck (MRK) reported five-year follow-up data from a Phase 2b trial showing their experimental cancer vaccine reduced melanoma recurrence or death risk by 49% when combined with Merck’s immunotherapy drug Keytruda 4,5. The personalized vaccine uses mRNA technology to target tumor-specific mutations.
The long-term data validates the durability of the treatment effect, addressing investor concerns about sustained efficacy. The companies are advancing the combination therapy into Phase 3 trials for adjuvant melanoma treatment.
Platform validation beyond COVID
The oncology results demonstrate Moderna’s mRNA platform versatility beyond infectious diseases. Analysts view this as crucial for the company’s long-term growth prospects as COVID vaccine demand normalizes 2.
“These results improve the platform’s value case,” according to investment analysts, who noted the data supports Moderna’s transition from a pandemic-focused company to a diversified biotechnology platform 2.
Partnership strategy pays off
The collaboration with Merck provides Moderna access to established oncology expertise and commercialization capabilities. Merck’s Keytruda generated over 25 billion in 2023 revenue, giving the partnership significant market reach.
The success could accelerate additional partnerships as Moderna expands its oncology pipeline. The company is developing multiple cancer vaccine candidates targeting various tumor types.
Looking ahead
Phase 3 trial results, expected in the coming years, will be critical catalysts for the cancer vaccine program. Regulatory approval could open a multibillion-dollar market opportunity in personalized cancer treatment.
Moderna’s stock performance will likely depend on continued pipeline progress and successful diversification beyond COVID products. The company faces increasing competition in both mRNA vaccines and cancer immunotherapy markets.
Not investment advice. For informational purposes only.
References
1Barron’s. “Moderna Stock Is Surging. Why a Cancer Vaccine Study Has Sparked a Rally”. Retrieved January 22, 2026.
2“Moderna Stock Rallies as Oncology Results Improve the Platform’s Value Case”. Investing.com. Retrieved January 22, 2026.
3“Moderna (MRNA) Touches 52-Week High on Strong Clinical Results”. FinViz. Retrieved January 22, 2026.
4“Moderna Stock Is Surging. Why a Cancer Vaccine Study Has Sparked a Rally”. Moomoo. Retrieved January 22, 2026.
5“Moderna’s 52-Week High: A Tactical Play on Phase 3 Catalysts”. AInvest. Retrieved January 22, 2026.